Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 16;23(3):33.
doi: 10.1007/s11912-021-01016-y.

Progress Update in Pediatric Renal Tumors

Juhi Jain  1   2   3 , Kathryn S Sutton  1   2   4 , Andrew L Hong  5   6   7   8
Affiliations
Review

Progress Update in Pediatric Renal Tumors

Juhi Jain et al. Curr Oncol Rep. .

Abstract

Purpose of review: Pediatric renal tumors account for 7% of new cancer diagnoses in children. Here, we will review results from recently completed clinical trials informing the current standard of care and discuss targeted and immune therapies being explored for the treatment of high risk or relapsed/refractory pediatric renal malignancies.

Recent findings: Cooperative group trials have continued to make improvements in the care of children with pediatric tumors. In particular, trials that standardize treatment of rare cancers (e.g., bilateral Wilms tumor) have improved outcomes significantly. We have seen improvements in event free and overall survival in recently completed clinical trials for many pediatric renal tumors. Still, there are subsets of rarer cancers where outcomes remain poor and new therapeutic strategies are needed. Future trials aim to balance treatment toxicity with treatment efficacy for those with excellent outcomes while identifying novel therapeutics for those with poor outcomes.

Trial registration: ClinicalTrials.gov NCT03155620.

Keywords: 1q Gain; AREN0321; AREN0532; AREN0533; AREN0534; Clear-cell sarcoma of the kidney; LOH 1p/16q; Malignant rhabdoid tumor; Mesoblastic nephromas; Pediatric renal tumors; Wilms tumor.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov ) SEER*Explorer database: incidence - SEER research data, kidney and renal pelvis cancer SEER incidence rates by age at diagnosis, Sub (2013-2017), National Cancer Institute, DCCPS, Surveillance Research Program. https://seer.cancer.gov/explorer/application.html?site = 72&data_type = 1&graph_type = 3&compareBy = sex&chk_sex_1 = 1&chk_sex_3 = 3&chk_sex_2 = 2&race = 1&rate_type = 1&advopt_precision = 1&advopt_display = 2. Accessed 7 Aug 2020
    1. Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, et al. Children’s Oncology Group’s 2013 blueprint for research: renal tumors. Pediatr Blood Cancer. 2013;60:994–1000.
    1. D’Angio GJ. The National Wilms tumor study: a 40 year perspective. Lifetime Data Anal. 2007;13:463–70. - DOI
    1. Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet. 2006;43:705–15. - DOI
    1. Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, et al. Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial: a SIOP renal tumours biology consortium study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3195–203.

Associated data